InfuSystem Holdings, Inc. (INFU)
| Market Cap | 209.41M +98.1% |
| Revenue (ttm) | 143.44M +6.4% |
| Net Income | 6.63M +182.6% |
| EPS | 0.31 +181.8% |
| Shares Out | 20.19M |
| PE Ratio | 33.45 |
| Forward PE | 24.93 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 123,024 |
| Open | 10.19 |
| Previous Close | 10.13 |
| Day's Range | 10.10 - 10.55 |
| 52-Week Range | 4.67 - 11.04 |
| Beta | 1.49 |
| Analysts | Strong Buy |
| Price Target | 15.00 (+44.65%) |
| Earnings Date | May 7, 2026 |
About INFU
InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps and related products and services in the United States and Canada. It operates through two segments: Patient Services and Device Solutions. The company supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. It also sells and rents new and pre-owned pole-mounted and ... [Read more]
Financial Performance
In 2025, InfuSystem Holdings's revenue was $143.44 million, an increase of 6.36% compared to the previous year's $134.86 million. Earnings were $6.63 million, an increase of 182.60%.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for INFU stock is "Strong Buy." The 12-month stock price target is $15.0, which is an increase of 44.65% from the latest price.
News
InfuSystem to Report First Quarter 2026 Financial Results on May 7, 2026
ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to Report First Quarter 2026 Financial Results on May 7, 2026.
InfuSystem to Participate at 38th Annual ROTH Conference on March 23, 2026
ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to Participate at 38th Annual ROTH Conference on March 23, 2026.
InfuSystem Holdings Earnings Call Transcript: Q4 2025
Q4 2025 saw 7% revenue growth and record adjusted EBITDA, with strong cash flow and a 30% net debt reduction. 2026 guidance calls for 6%-8% revenue growth, stable margins, and continued focus on Patient Services and new product launches.
InfuSystem Announces Financial Results for Fourth Quarter and Full Year 2025
ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem Announces Financial Results for Fourth Quarter and Full Year 2025.
InfuSystem to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026.
Ambulatory Infusion Pumps used in Pain Management Business by InfuSystem to Receive Separate Payment Under NOPAIN Act Starting January 1, 2026
ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--Ambulatory Infusion Pumps used in Pain Management Business by InfuSystem to Receive Separate Payment Under NOPAIN Act Starting January 1, 2026.
InfuSystem to Participate at 16th Annual Craig-Hallum Alpha Select Conference on November 18, 2025
ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to Participate at 16th Annual Craig-Hallum Alpha Select Conference on November 18, 2025.
InfuSystem Holdings Earnings Call Transcript: Q3 2025
Q3 2025 delivered record revenue and margin expansion, led by patient services growth in oncology and wound care. A major biomedical contract was amended, reducing revenue but boosting operating profit, while automation and new contracts support future growth.
InfuSystem Reports Third Quarter 2025 Financial Results
ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem Reports Third Quarter 2025 Financial Results.
InfuSystem to Report Third Quarter 2025 Financial Results on November 4, 2025
ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to Report Third Quarter 2025 Financial Results on November 4, 2025.
InfuSystem to Present at 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025
ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to Present at 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025.
InfuSystem Holdings Earnings Call Transcript: Q2 2025
Q2 saw record revenue, margin expansion, and a 32% rise in adjusted EBITDA, with strong cash flow and reduced capital expenditures. 2025 revenue guidance was lowered, but EBITDA margin guidance increased, reflecting operational efficiency and strategic investments.
InfuSystem Reports Second Quarter 2025 Financial Results
ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem Reports Second Quarter 2025 Financial Results.
InfuSystem to Report Second Quarter 2025 Financial Results on August 5, 2025
ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to Report Second Quarter 2025 Financial Results on August 5, 2025.
InfuSystem Holdings Earnings Call Transcript: Q1 2025
Revenue grew 8.5% year-over-year in Q1 2025, with Adjusted EBITDA up 64% and margins at multi-year highs. Both Patient Services and Device Solutions segments contributed to growth, and full-year guidance calls for 8%-10% revenue growth and higher margins despite ongoing IT upgrade costs.
InfuSystem Reports First Quarter 2025 Financial Results
ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem Reports First Quarter 2025 Financial Results.
InfuSystem to Report First Quarter 2025 Financial Results on May 8, 2025
ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to Report First Quarter 2025 Financial Results on May 8, 2025.
InfuSystem Announces CEO Transition; Carrie Lachance to Become Chief Executive Officer
ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem Announces CEO Transition; Carrie Lachance to Become Chief Executive Officer.
InfuSystem Holdings Earnings Call Transcript: Q4 2024
Revenue grew 7.2% in 2024, with gross margin up 2% and adjusted EBITDA up 13%. 2025 guidance calls for 8–10% revenue growth and higher EBITDA margins, driven by advanced wound care, biomed, and Chemo Mouthpiece adoption. Net debt fell to $23.3M, with strong liquidity and capital discipline.
InfuSystem Announces Operational and Financial Results for Fourth Quarter and Full Year 2024
ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem Announces Operational and Financial Results for Fourth Quarter and Full Year 2024.
InfuSystem to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025
ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025.
InfuSystem Holdings Transcript: The Sidoti Small-Cap Virtual Investor Conference
The company is leveraging its core strengths in logistics, biomedical services, and revenue cycle management to expand beyond its dominant oncology business into wound care and new product lines like Chemo Mouthpiece. Strong partnerships, improved margins, and robust cash flow position it for continued growth and profitability in 2025.
InfuSystem to Present at Sidoti Small Cap Conference on December 4, 2024
ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to Present at Sidoti Small Cap Conference on December 4, 2024.
InfuSystem Appoints Ronald Hundzinski to the Board of Directors
ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem Appoints Ronald Hundzinski to the Board of Directors.
InfuSystem Holdings Earnings Call Transcript: Q3 2024
Record Q3 revenue and profitability were driven by double-digit growth in both Device Solutions and Patient Services, with strong cash flow enabling debt reduction and share repurchases. New agreements in wound care, biomedical services, and oncology position the company for continued growth into 2025.